Buchumschlag

Risk of suicidal ideation and suicidality among adults prescribed semaglutide for weight management: A population‐based cohort study

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Qoua L. Her, Tiansheng Wang, Til Stürmer, John B. Buse, Michele Jonsson Funk, Virginia Pate, Michael Webster‐Clark
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Diabetes, Obesity and Metabolism
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Validation of an international classification of disease, tenth revision, clinical modification ( ICD‐10‐CM ) algorithm in identifying severe hypoglycaemia events for real‐world studies
von: Qoua L. Her, et al.
Veröffentlicht: (2024)

Newer glucose‐lowering drugs and risk of suicidal ideation and behaviours: A network meta‐analysis of randomized outcome trials
von: Ying Lu, et al.
Veröffentlicht: (2024)

Survey among adult users of semaglutide for weight loss in Denmark: User characteristics, treatment expectations and experienced effects
von: Malene Svoldgaard Sørensen, et al.
Veröffentlicht: (2025)

Real‐world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic
von: Jason M. Samuels, et al.
Veröffentlicht: (2025)

Effect of semaglutide add‐on therapy for people living with type 1 diabetes and excess weight
von: Noga C. Minsky, et al.
Veröffentlicht: (2025)

Treat to target in weight management with semaglutide: Real‐world evidence from an eHealth clinic
von: Søren Seier, et al.
Veröffentlicht: (2025)

Glycaemic and weight effects of metabolic surgery or semaglutide in diabetes dosage for patients with type 2 diabetes
von: Erik Stenberg, et al.
Veröffentlicht: (2024)

Association of oral semaglutide with cardiovascular outcomes in a real‐world primary prevention population
von: Kevin Cowart, et al.
Veröffentlicht: (2025)

Association between weight‐adjusted‐waist index and incident carotid atherosclerosis in the general adult population in Chinese communities: Evidence from the REACTION cohort study
von: Qingzheng Wu, et al.
Veröffentlicht: (2025)

Effect of semaglutide 2.4 mg on physical functioning and weight‐ and health‐related quality of life in adults with overweight or obesity: Patient‐reported outcomes from the STEP 1–4 trials
von: Domenica Rubino, et al.
Veröffentlicht: (2024)

Post‐semaglutide weight regain in females with obesity: Associations with gut microbiota, bile acid metabolism, and central nervous system
von: Ning Wang, et al.
Veröffentlicht: (2026)

Oral or injectable semaglutide for the management of type 2 diabetes in routine care: A multicentre observational study comparing matched cohorts
von: Gian Paolo Fadini, et al.
Veröffentlicht: (2024)

Improved health‐related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT ‐5 trial
von: Alpana P. Shukla, et al.
Veröffentlicht: (2025)

Association between glucagon‐like peptide ‐1 receptor agonists and risk of suicidality: A comprehensive analysis of the global pharmacovigilance database
von: Tae Hyeon Kim, et al.
Veröffentlicht: (2024)

Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial
von: Maria Buur Nordskov Gabe, et al.
Veröffentlicht: (2024)

Diabetic kidney disease: The fourth pharmacological pillar may be semaglutide
von: Dario Giugliano, et al.
Veröffentlicht: (2024)

Association of semaglutide with less limb events in people with type 2 diabetes and peripheral artery disease or foot ulcers: An observational study comparing matched cohorts
von: Paola Caruso, et al.
Veröffentlicht: (2025)

Comparison of cardiovascular outcomes between once‐weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States
von: Xi Tan, et al.
Veröffentlicht: (2026)

Is the combination of resmetirom and semaglutide useful for the treatment of metabolic dysfunction‐associated steatohepatitis?
von: Stergios A. Polyzos, et al.
Veröffentlicht: (2026)

Impact of baseline characteristics on the efficacy of once‐weekly subcutaneous semaglutide among participants with type 2 diabetes : A post hoc analysis of SUSTAIN China
von: Linong Ji, et al.
Veröffentlicht: (2024)

Real world study provided reassurance of the safety of GLP‐1 therapy on mental health and suicide risk
von: Iskandar Idris
Veröffentlicht: (2024)

Efficacy and safety of once‐weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial
von: Weijun Gu, et al.
Veröffentlicht: (2025)

Real‐world evaluation of clinical outcomes in Dutch patients with type 2 diabetes treated with oral semaglutide: A retrospective, observational cohort study using the PHARMO data network
von: Abigail Postema, et al.
Veröffentlicht: (2025)

PIONEER REAL Saudi Arabia: A multicentre, prospective, real‐world study of once‐daily oral semaglutide use in adults with type 2 diabetes in Saudi Arabia
von: Hussein ElBadawi, et al.
Veröffentlicht: (2025)

Treatment effect of semaglutide 2.4 mg on health‐related quality of life from STEP 1 SF‐6D derived from SF ‐36 with Australian weights
von: Pavol Kral, et al.
Veröffentlicht: (2024)

Real‐world glycated haemoglobin changes among type 2 diabetes mellitus patients treated with a maintenance dose of 7 mg or 14 mg of oral semaglutide
von: Caroline Swift, et al.
Veröffentlicht: (2024)

Oral semaglutide and survival in heart failure with preserved ejection fraction and type 2 diabetes
von: Takefumi Kishimori, et al.
Veröffentlicht: (2026)

Medical events and costs associated with metabolic bariatric surgery among adults with type 2 diabetes: A retrospective, matched cohort study
von: Kristina S. Boye, et al.
Veröffentlicht: (2025)

Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction‐associated steatotic liver disease: Post hoc analysis of three randomised controlled trials
von: Matthew J. Armstrong, et al.
Veröffentlicht: (2024)

Changes to insulin requirements over time with semaglutide in adults with type 1 diabetes on insulin pump therapy: A post‐hoc analysis of a double‐blinded, randomised, crossover trial
von: Melissa‐Rosina Pasqua, et al.
Veröffentlicht: (2025)

Exploring population and sex‐specific disease trajectories for multimorbidities among individuals with overweight or obesity: A retrospective cohort study in UK biobank
von: Qianhui Lu, et al.
Veröffentlicht: (2025)

Long‐acting insulin analogues and the risk of diabetic nephropathy among patients with type 2 diabetes: A population‐based cohort study
von: Julia Brillinger, et al.
Veröffentlicht: (2026)

Metformin and risk of adverse pregnancy outcomes among pregnant women with gestational diabetes in the United Kingdom: A population‐based cohort study
von: Ya‐Hui Yu, et al.
Veröffentlicht: (2024)

Efficacy and safety of once‐weekly subcutaneous semaglutide 2.4 mg for the management of overweight or obesity in Asian populations: A systematic review, meta‐analysis and meta‐regression of randomised trials
von: Hendra Zufry, et al.
Veröffentlicht: (2025)

The effect of semaglutide on intestinal iron absorption in patients with type 2 diabetes mellitus—A pilot study
von: Petra Melis, et al.
Veröffentlicht: (2025)

Cost‐utility analysis and drug pricing for tirzepatide for type 2 diabetes in the Chinese market compared with semaglutide
von: Shanshan Hu, et al.
Veröffentlicht: (2024)

Biological aging mediates the associations of metabolic score for insulin resistance with all‐cause and cardiovascular disease mortality among US adults: A nationwide cohort study
von: Xiaoxuan Li, et al.
Veröffentlicht: (2024)

Efficacy and safety of oral semaglutide treatment in a Danish type 2 diabetes outpatient clinic: Real‐world evidence
von: Alexandra A. Weinreich, et al.
Veröffentlicht: (2025)

Risk stratification using coronary artery calcium and potential benefit of semaglutide therapy: A cost‐effectiveness modelling study
von: Sai Rahul Ponnana, et al.
Veröffentlicht: (2026)

Patterns of initial and first‐intensifying antidiabetic drug utilization among patients with type 2 diabetes mellitus in Scotland, 2010–2020: A retrospective population‐based cohort study
von: Fatema Mahmoud, et al.
Veröffentlicht: (2024)